Technical Description
The present invention provides fluorescence-emitting labelling agents detects β amyloid aggregates simultaneously inhibits cholinesterase enzymes for the management of Alzheimer’s disease. The compounds show strong Blood Brain Barrier (BBB) permeability and enhanced fluorescence for imaging in the CNS.
Problems Addressed
- Method Complexity
- Low Quantum Yield
- Limitations of Conventional Techniques
- No Early Aβ Detection
Tech Features
- Near-Infrared Fluorescence
- AChE Inhibition
- Aβ Aggregates Detection
- Scalable
- BBB Permeability
- Quantum Yield Optimization
Target Audience
- Healthcare and Medical Sector
- Pharmaceutical Industry
- Biotechnology Industry
- Research and Development
Tech ID: P35-1425 TRL 4 Patent Status: Published Available For Exclusive and Non-exclusive License
